Rochester has been chosen as one of four national sites to monitor the effectiveness of the new cervical cancer vaccine. The project, which is funded by the national Centers for Disease Control and Prevention (CDC), will be jointly conducted by the University of Rochester Medical Center (URMC) and the New York State Department of Health.“Rochester has a strong history of coming together as a community to evaluate new vaccines and improve vaccination rates,” said Nancy M. Bennett, M.D., M.S., director of the URMC Center for Community Health. “This study is critical because many of the fundamental questions about a new vaccine cannot really be answered until we have been able to look at its impact on a broad population over a long period of time.”
